ViiV Poised To Take HIV PrEP Injectable In Late-Stage Trials
Executive Summary
ViiV Healthcare is set to start Phase III studies of its next-generation integrase inhibitor cabotegravir as a long-acting injectable for the prevention of HIV. The head-to-head study will compare it with Gilead’s market leading oral PrEP therapy Truvada in pre-exposure prohylaxis in both men and women.
You may also be interested in...
Truvada Sales To Rise On EU Okay In HIV Prevention; UK Use Uncertain
The EU’s approval of Gilead’s Truvada for pre-exposure prophylaxis makes it the first medicine licensed in Europe to reduce the risk of HIV transmission through sexual intercourse and puts pressure on Britain’s reluctant, cash-strapped National Health Service to provide public funding for the drug’s preventative use.
ViiV Starts Phase III With Two-Drug HIV Regimen In Naïve Patients
ViiV Healthcare begins a Phase III program for a two-drug regimen for adults with HIV who are treatment naïve, however, clinical data proving both long-term safety and efficacy will be crucial for commercial success.
ViiV’s Visibility Grows And Pressure Mounts For What Comes Next
GlaxoSmithKline’s HIV-focused business unit is growing leaps and bounds, while the company’s other pharmaceutical sales slump. ViiV CEO Dominique Limet talked in an interview about the increased pressure success brings and how ViiV intends to keep delivering.